Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
Exclusive-Licensing Partner Santen Will Commercialize SYD-101 Under the Brand Name Ryjunea® in the European Union DEL MAR, Calif. – June 5, 2025 – (BUSINESS WIRE) Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company’s proprietary low-dose atropine formulation, for slowing the […]
FDA Grants Atia Vision Approval to Begin US Clinical Trial of OmniVu™ Lens System in Patients with Cataracts
The OmniVu is arevolutionary dual-optic lens designed to restore dynamic visual function by harnessing the eye’s natural accommodative mechanism while preserving its anatomical integrity. Global clinical trials show promising long-term predictability and stability in more than 75 treated eyes. CAMPBELL, Calif.–(BUSINESS WIRE)–Atia Vision, Inc., a Shifamed portfolio company, today announced it has received Investigational Device […]
Julius Clinical and Peachtree BioResearch Solutions Merge to Form a Fully Integrated Global CRO with Increased CNS Capabilities
Zeist, Netherlands, May 14, 2025– Julius Clinical, a leading full-service Contract Research Organization (CRO) headquartered in the Netherlands (Zeist), and Peachtree BioResearch Solutions, a specialized CNS CRO based in the United States (Georgia), announce they have merged as a fully integrated clinical research organization. The merger combines scientific and operational excellence, an expanded international footprint […]
